Rare & Orphan Lab · DeCure for X

DeCure for Lymphadenitis

DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for lymphadenitis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.

Disease module1 genesLead labRare & Orphan
All cures
Rare & OrphanDOID:1602$DeCureRare

The disease map

Disease moduleLymphadenitis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.

Research record

01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash

Current lead

No approved-drug candidate for lymphadenitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.

Evidence

Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.

Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access

MEASURES TO PREVENT AND TREAT LYMPHADENITIS DISEASE.

AbstractLymphadenitis is an inflammation of the lymph nodes that occurs as a result of a reaction to a chronic or aggravated serious disease in the body. A lymph node is a collection of lymph vessels that produce specialized cells to fight infection, organ or tissue disease. In this article, we will inform people about lymphadenitis, that is, the disease, its types, causes, treatment, etc.

https://doi.org/10.5281/zenodo.7751370
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access

MEASURES TO PREVENT AND TREAT LYMPHADENITIS DISEASE.

AbstractLymphadenitis is an inflammation of the lymph nodes that occurs as a result of a reaction to a chronic or aggravated serious disease in the body. A lymph node is a collection of lymph vessels that produce specialized cells to fight infection, organ or tissue disease. In this article, we will inform people about lymphadenitis, that is, the disease, its types, causes, treatment, etc.

https://doi.org/10.5281/zenodo.7751371

Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.

DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.